Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MEREO BIOPHARMA GROUP PLC

(MREO)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
0.8417 USD   -3.38%
09/23Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders
CI
09/22European ADRs Move Lower in Thursday Trading
MT
09/21European ADRs Move Lower in Wednesday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Mereo BioPharma Group plc is a United Kingdom-based biopharmaceutical company. The Company is focused on the development of therapeutics that aim to improve outcomes for oncology and rare diseases and focuses on commercializing selected rare disease programs. Its portfolio consists of six clinical-stage product candidates two of which, Etigilimab (MPH-313) and Alvelestat (MPH-966), are in ongoing clinical studies. Its lead oncology product candidate, MPH-313 is an anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody. Its second oncology product, Navicixizumab (OMP-305B83) is used for the treatment of late line ovarian cancer. Its rare disease product candidates are Alvelestat, is for the treatment of severe alpha-1 antitrypsin deficiency (AATD). Its Setrusumab (BPS-804) is an antibody designed to inhibit sclerostin, a protein that inhibits the activity of bone-forming cells. Its other product candidates include Acumapimod (BCT-197) and Leflutrozole (BGS-649).

Number of employees : 45 people.
Managers
Name Title Age Since
Denise Vera Scots-Knight, Dr. Chief Executive Officer & Director 61 2015
Christine Fox Chief Financial Officer 40 2021
John A. Lewicki, Dr. Chief Scientific Officer 69 2020
Suba Krishnan, Dr. Senior Vice President-Clinical Development 56 2020
Charles Edward Sermon Secretary & General Counsel 52 2015
John P. Richard Chief Business Officer 63 -
Alastair Graham MacKinnon, Dr. Chief Portfolio Management & Pipeline Strategy 50 2021
Wills Hughes-Wilson Chief Patient Access & Commercial Planning 50 -
Richard Francis Senior VP-CMC & Manufacturing Operations - -
Ann Kapoun, Dr. Senior VP-Translational Research & Development - 2020
Members of the board
Name Title Age Since
Michael S. Wyzga Chairman 66 2022
Anders Olof Adolf Ekblom Independent Non-Executive Director 67 2015
Peter John Fellner, Dr. Vice Chairman 77 2022
Deepa R. Pakianathan, Dr. Independent Non-Executive Director 56 2019
Denise Vera Scots-Knight, Dr. Chief Executive Officer & Director 61 2015
Brian D. Schwartz, Dr. Director 49 2020
Jeremy Bender, Dr. Director 59 2020
Pierre Jacquet, Dr. Director 54 2021
Abdul Mullick, Dr. Director - 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 584,908,239 301,926,833 51.6% 0 0.0% 51.6%
Shareholders
NameEquities%
Rubric Capital Management LP 16,756,120 14.4%
Point72 Asset Management LP 10,035,970 8.60%
Suvretta Capital Management LLC 9,142,067 7.83%
OrbiMed Advisors Private Equity 7,109,954 6.09%
Rock Springs Capital Management LP 6,230,275 5.34%
Vivo Capital LLC 3,795,225 3.25%
Clearline Capital LP 3,058,596 2.62%
HHLR Advisors Ltd. 2,976,121 2.55%
Citadel Advisors LLC 2,647,287 2.27%
Holocene Advisors, LP 2,532,204 2.17%
Company contact information
Mereo BioPharma Group Plc
1 Cavendish Place
4th Floor
London, Greater London W1G 0QF

Phone : +44.333.023.7300
Web : http://www.mereobiopharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Mereo BioPharma Group plc